SEARCH:   Advanced

Blood, 1 February 2006, Vol. 107, No. 3, pp. 880-884. Prepublished online as a Blood First Edition Paper on August 25, 2005; DOI 10.1182/blood-2005-06-2450. This Article Full Text (PDF) All Versions of this Article: 2005-06-2450v1 107/3/880    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oki, Y. Articles by Garcia-Manero, G. Search for Related Content PubMed PubMed Citation Articles by Oki, Y. Articles by Garcia-Manero, G. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 21, 2005 Accepted July 22, 2005 Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center Yasuhiro Oki, Hagop M Kantarjian, Xian Zhou, Jorge Cortes, Stefan Faderl, Srdan Verstovsek, Susan O'Brien, Charles Koller, Miloslav Beran, B. Nebiyou Bekele, Sherry Pierce, Deborah Thomas, Farhad Ravandi, William G Wierda, Francis Giles, Alessandra Ferrajoli, Elias Jabbour, Michael J Keating, Carlos E Bueso-Ramos, Elihu Estey, and Guillermo Garcia-Manero* Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Biostatistics and Applied Mathematics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA * Corresponding author; email: ggarciam{at}mdanderson.org. To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D. Anderson Cancer Center between 1987 and 2003, and compared them with 1800 patients with non-M7, non-M3, AML treated during the same period. The median age of the M7 AML group was 56 years (range 21-78); 22 patients (59%) had antecedent hematologic disorder and/or myelodysplastic syndrome; and 7 patients (19%) had previously received chemotherapy for other malignancies. Extensive bone marrow fibrosis was found in 23 patients (62%). Poor cytogenetic characteristics were observed in 49% of patients with M7 AML versus 33% of others (p< 0.0001). Complete remission rates were 43% with M7 AML, and 57% with non-M7 AML (p= 0.089). Median overall survival (OS) was 23 and 38 weeks, respectively (p= 0.006). Median disease-free survivals were 23 versus 52 weeks, respectively (p< 0.0001). By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, p= 0.049). These results confirm the poor prognosis of M7 AML, and indicate that other biological characteristics beyond cytogenetic abnormalities likely play a role in this disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Edwards, C. Xie, K. M. LaFiura, A. A. Dombkowski, S. A. Buck, J. L. Boerner, J. W. Taub, L. H. Matherly, and Y. Ge RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia Blood, September 24, 2009; 114(13): 2744 - 2752. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020